Colorectal Cancer

Phase 2 data show that vaccination with PolyPEPI1018 may enhance the efficacy of atezolizumab in those with microsatellite stable metastatic CRC.

The addition of liver transplant to chemotherapy in those with colorectal cancer and liver metastases boosted overall survival.

Surgical oncologists from Cleveland Clinic discuss the National Accreditation Program for Rectal Cancer and its aim to improve patient outcomes.

Treatment with complete mesocolic excision appears to reduce the length of hospital stay compared with conventional surgery in right colon cancer.

Investigators may continue to reevaluate the benefits of the AI navigator MyEleanor over time in other patient populations.

Determining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.

Gregory Charak, MD, discusses how modalities like laparoscopic surgery and neoadjuvant immunotherapy may benefit patients with colorectal cancer.

Data from the phase 3 CRC-PREVENT trial support the sensitivity of ColoSense in the detection of colorectal cancer.

CheckMate-8HW assessed the efficacy of first-line nivolumab plus ipilimumab in patients with MSI-H/dMMR metastatic colorectal cancer.

Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.

Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.

Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.

ME-344 and bevacizumab can now have an additional 20 patients enrolled on the phase 1b trial for relapsed metastatic colorectal cancer.

Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.

Patients who are African American appeared to have worse clinical stages of colon and rectal cancer during surgery in 2020.

Data from the phase 1/2 KRYSTAL-1 trial may support adagrasib plus cetuximab as a new standard in previously treated metastatic KRAS G12C–mutated CRC.

The PREEMPT trial analyzed samples from 27,010 average-risk adults to determine the specificity of detecting colorectal cancer.

Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.

If possible, targeting the BER pathway for drug sensitivities may increase therapeutic options for managing solid cancers, wrote Channing Paller, MD.

Long-term circulating tumor DNA responses appear to align with progression-free survival trends in a phase 2/3 trial of the GRANITE vaccine in those with microsatellite-stable colorectal cancer.

Gut microbiome signatures may lead the way for more accurate treatments and diagnoses for patients with colorectal cancer.

Investigators will assess A2B530 as a treatment for patients with germline heterozygous HLA-A*02–positive colorectal cancer expressing carcinoembryonic antigen in the phase 1/2 EVEREST-1 trial.

Panitumumab plus modified FOLFOX6 appears to increase survival among patients with metastatic colorectal cancer and circulating tumor DNA that has no gene alterations in the PARADIGM trial.

The expert panel provides a comprehensive overview of the COSMOS-CRC-03 study and touch on the importance of also looking at real-world data.

An overview of prospective trial data surrounding MRD testing in early-stage CRC and the impact of these findings on the overall treatment landscape.